COVID-19 Treatment Update - Dec 2021
Ronapreve®
Therapeutic options for COVID-19 continue to advance not just for severe disease but also for milder disease. Clinical trials are ongoing for antiviral tablets in community based settings and we await further information on how these will be deployed in due course.
For hospitalised patients, Ronapreve® (casirivimab and imdevimab) is a monoclonal antibody combination which has recently been added as a therapeutic option alongside oxygen, dexamethasone, Interleukin-6 (IL-6) receptor antagonists (sarilumab or tocilizumab) and sometimes IV antiviral medications. Ronapreve® is now indicated in two distinct patient populations:
Group 1: Patients admitted unwell with COVID-19 who are negative for baseline serum anti-spike (anti-S) antibodies against SARS-CoV-2.
Group 2: Patients with early hospital onset COVID-19 who are at high risk of progression to severe COVID-19 or in whom COVID-19 infection presents a material risk of destabilising a pre-existing condition or illness or compromising recovery from surgery or other hospital procedure.
You can find further information in the GGC Adult Therapeutics Handbook COVID-19 guideline which has been updated. Hospital based doctors and other healthcare professionals are encouraged to update their knowledge on COVID-19 therapeutics.
Published: 10/12/2021. Medicines Update blogs are correct at the time of publication